je.st
news
Amgen announces submission of supplemental New Drug Application to FDA for Kyprolis
2015-07-23 21:20:21| Biotech - Topix.net
Amgen today announced the submission of a supplemental New Drug Application to the U.S. Food and Drug Administration for Kyprolis for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. Kyprolis currently has accelerated approval in the U.S. for the treatment of patients with relapsed multiple myeloma as a monotherapy.
Tags: application
drug
submission
announces
Category:Biotechnology and Pharmaceuticals